Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2024

Steroid refractory acute graft-versus-host disease - Pipeline Insight, 2024

DelveInsight’s, “Steroid Refractory Acute Graft-Versus-Host Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Steroid Refractory Acute Graft-Versus-Host Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Steroid Refractory Acute Graft-Versus-Host Disease Understanding

Steroid Refractory Acute Graft-Versus-Host Disease: Overview

Acute graft-versus-host disease (aGVHD) is a usual complication associated with allogeneic hematopoietic stem cell transplantation (alloHCT). This disease is a major cause of morbidity. Systemic steroid therapies are the standard first line therapy for aGVHD. However, 35-50% of patients with aGVHD become refractory to systemic steroid therapy. The disease develops in the skin, GI tract, and liver of the patients with alloHCT. Symptoms depend on the severity of aGVHD and include maculopapular rash, vomiting, nausea, abdominal cramps, watery diarrhea, and hyperbilirubinemia with jaundice.

""Steroid Refractory Acute Graft-Versus-Host Disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Steroid Refractory Acute Graft-Versus-Host Disease pipeline landscape is provided which includes the disease overview and Steroid Refractory Acute Graft-Versus-Host Disease treatment guidelines. The assessment part of the report embraces, in depth Steroid Refractory Acute Graft-Versus-Host Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Steroid Refractory Acute Graft-Versus-Host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Steroid Refractory Acute Graft-Versus-Host Disease R&D. The therapies under development are focused on novel approaches to treat/improve Steroid Refractory Acute Graft-Versus-Host Disease.

Steroid Refractory Acute Graft-Versus-Host Disease Emerging Drugs Chapters

This segment of the Steroid Refractory Acute Graft-Versus-Host Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Steroid Refractory Acute Graft-Versus-Host Disease Emerging Drugs

● Itacitinib: Incyte Corporation

Incytes’ novel drug candidate, Itacitinib, is an orally administered small molecule in development for the treatment of steroid refractory aGVHD. The drug is a selective inhibitor of JAK-1 and given in combination with corticosteroids for treating acute as well as chronic aGVHD. The drug has received orphan drug status and has demonstrated good efficacy results in its phase II trial and currently undergoing phase 3 of clinical trials.

● Glassia: Kamada

Kamada’s “lead” drug Glassia which is an immunomodulator as well as serine endopeptidase inhibitors molecule is currently being evaluated for the treatment of steroid refractory aGVHd snf has demonstrated good safety and efficacy profile in its earlier phase trials.

Further product details are provided in the report……..

Steroid Refractory Acute Graft-Versus-Host Disease : Therapeutic Assessment

This segment of the report provides insights about the different Steroid Refractory Acute Graft-Versus-Host Disease drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Steroid Refractory Acute Graft-Versus-Host Disease

There are approx. 10+ key companies which are developing the therapies for Steroid Refractory Acute Graft-Versus-Host Disease. The companies which have their Steroid Refractory Acute Graft-Versus-Host Disease drug candidates in the most advanced stage, i.e. phase III include, Incyte Corporation.

● Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

● Route of Administration

Steroid Refractory Acute Graft-Versus-Host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

● Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Steroid Refractory Acute Graft-Versus-Host Disease : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Steroid Refractory Acute Graft-Versus-Host Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Steroid Refractory Acute Graft-Versus-Host Disease drugs.

Steroid Refractory Acute Graft-Versus-Host Disease Report Insights

• Steroid Refractory Acute Graft-Versus-Host Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Steroid Refractory Acute Graft-Versus-Host Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Steroid Refractory Acute Graft-Versus-Host Disease drugs?
• How many Steroid Refractory Acute Graft-Versus-Host Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Steroid Refractory Acute Graft-Versus-Host Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Steroid Refractory Acute Graft-Versus-Host Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Steroid Refractory Acute Graft-Versus-Host Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

● Incyte Corporation

● Kamada

● Medac

● ElsaLys Biotech

● Pfizer

Key Products

• Itacitinib
• Glassia
• MC0518
• Inolimomab
• Etanercept